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Background. Parkinson disease (PD) is a costly chronic condition in terms of managing both motor and nonmotor symptoms.The
burden of disease is high for individuals, caregivers, and the health system.The aim of this study is to estimate the annual cost of PD
from the household, health system, and societal perspectives.Methods. A prospective cohort study of newly referred people with PD
to a specialist PD clinic in Melbourne, Australia. Participants completed baseline and monthly health resource use questionnaires
and Medicare data were collected over 12 months. Results. 87 patients completed the 12-month follow-up assessments. The mean
annual cost per person to the health care system was $32,556 AUD. The burden to society was an additional $45,000 per annum
per person with PD.The largest component of health system costs were for hospitalisation (69% of total costs).The costs for people
with moderate to severe disease were almost 4 times those with mild PD ($63,569 versus $17,537 𝑝 < 0.001). Conclusion. PD is
associated with significant costs to individuals and to society. Costs escalated with disease severity suggesting that the burden to
society is likely to grow with the increasing disease prevalence that is associated with population ageing.
1. Introduction
Parkinson’s disease (PD) is a chronic and degenerative neuro-
logical condition that is associated with lifelong disability [1].
Movement disorders such as slowness, balance impairment,
tremor, freezing, and rigidity are characteristic of PD and
nonmotor symptoms such as anxiety, depression, fatigue, and
cognitive impairment are common [2]. Modified Hoehn and
Yahr (HY) score is the clinical ratingmethod to determine the
level/severity of motor function in people with PD [3]. Pro-
gression inHY stages correlates with deterioration in an indi-
vidual’s quality of life [4, 5]. As the disease progresses, people
with PD become highly vulnerable to falls and fall-related
injuries [6]. The range of symptoms associated with PD
means that the disease burden to the household (individual
and family), health system, and society is usually significant.
Parkinson’s disease is the second most common neuro-
logical disorder after Alzheimer’s disease [1, 7]. The number
of new cases of PD inAustralia grew by 17%during the period
2005 to 2011 [8]. Average life expectancy after a diagnosis of
PD is around 12 years although people can live more than 20
years with comprehensive care [9]. A European study of six
countries highlighted that 160 in 100,000 people aged 65 years
and older population have a diagnosis of PD and in future this
will increase with rapid population aging [10].
A US study estimated that the annual health system cost
of PD per person was in the range $1,750–$17,560 USD in
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2002 [11] but in 2010 this was closer to $23,000 USD per
person with the national burden of PD exceeding $14 billion
USD [12]. In Australia the cost to the individual with PD was
more than $15,000 per year in 2011 [8].There was a significant
burden to the health system ($8,000 per year in 2014 [8])
including hospitalisations and pharmaceutical and medical
services. A recent prospective cohort study indicated that
medication expenses contributed nearly 35% of total health
system costs related to PD [13]. People with PD and their
families also face significant out-of-pocket expenses for care-
giving and loss of productivity [14].
A number of international and Australian studies have
investigated the health-related quality of life (HRQOL) of
people with PD [5, 15]. Several studies have evaluated the
economic burden related to caring for people with PD [13,
16–18] and some have focused on the association between
resource utilisation and disease severity [18].
Given the paucity of recent data on the costs of PD, the
aim of this paper is to estimate the costs of PD over 12
months from the perspective of the household, the health
system, and society. A secondary aim is to investigate the
impact of disease severity on annual costs and resource
use.
2. Methodology
2.1. Study Design. This was a prospective cohort study with a
12-month follow-up conducted in Melbourne, Australia.
2.2. Study Population. The target population were people
with idiopathic PD who were newly referred to a specialist
PD clinic in metropolitan Melbourne [19]. Inclusion criteria
for the study were (i) confirmed diagnosis of idiopathic PD;
(ii) informed consent to participate in the study; (iii) ability
to attend assessment clinics; and (iv) ability to complete
questionnaires over 12 months. Exclusion criteria were (i)
coexisting neurological conditions and (ii) disease category
of HY stage five. Participants were also asked to consent
to retrieval of their data from Medicare Australia, but non-
consent did not preclude them from participating in this
study.
2.3. Ethics Approval. Ethics approvals were obtained from the
SouthernHealth Human Research Ethics Committee (HREC
number 06107B) and Monash University Standing Commit-
tee onEthics inResearch InvolvingHumans (SCERHnumber
2006/728MCC).
2.4. Data Collection. Participant’s health services resource
utilisation over 12 months was assessed through a series of
questionnaires administered monthly, at baseline, 3 months,
and 12 months. The baseline and 3- and 12-month question-
naires assessed PD duration and severity. Home based care
services and community services (informal care, formal care,
and meal-on-wheels) were also collected at 3 and 12 months.
Participants were assessed by a trained assessor at home, or
outpatient clinic [19]. Data related to health service resource
use were collected via the monthly questionnaires [19].These
included questions to assess hospital admissions (length of
stay, name of hospital, and method of transport to hospital),
medical services (general practitioner, medical specialist,
imaging services, and pathologist), and allied health services
(physiotherapy, podiatry, etc.). Monthly questionnaires were
completed with the help of a project officer who met with
participants. Where participants consented, individual data
on medical services and pharmaceutical use over 12 months
were obtained from the national insurer, Medicare Australia.
Resources were categorised according to the perspective of
the analysis: individual/household, health system, or limited
societal (inclusive of informal care but not productivity
losses). Table 1 shows the sources of data collection and
perspective for cost estimates.
2.5. Cost Analysis. Costs were attributed to self-reported
resource utilisation according to service category. Costs for
Medicare Australia data were reported as the individual out-
of-pocket component, government cost (benefit paid) and
societal cost (out-of-pocket + government). All costs are
reported in 2012 Australian dollars.
2.5.1. Hospitalisation. Hospitalisation data including number
of admissions and total length of stay (LOS) over a 12-month
period for both private and public hospitals for all causeswere
obtained from self-report via the monthly questionnaires. To
estimate the cost of hospitalisation per participant, the mean
cost of a hospital admission per day was calculated using
the national average cost per weighted separation from the
Independent Hospital Pricing Authority (IHPA) [21] and the
average hospital length of stay from theAustralian Institute of
Health and Welfare (AIHW) [20] according to the formulas
shown in Table 2. Where resource data were missing from
the monthly questionnaires, data for the number of hospital
admissions and total length of stay over 12 months were
imputed based on a weighted average from the available data
for each participant.
2.5.2. Medical Services and Pharmaceuticals. Medicare Aus-
tralia datawere obtained for consenting participants and used
to determine the total charges and benefits paid for visits to
general practitioners, medical specialists (including private
hospital visits), pathology, imaging, and pharmaceuticals
over 12 months. For participants who did not consent to
Medicare data an imputation method was used to replace
missing data based on disease severity according toHY score;
less than 2.5 formild disease andmoderate to severe ifHYwas
equal to or more than 2.5 [7].
2.5.3. Allied Health Services. The costs of physiotherapy and
podiatry services were estimated from both Medicare data
and self-reported data taken from resource use question-
naires. Where both sources of data overlapped, preference
was given to Medicare data. Costs for occupational ther-
apy, speech therapy, psychology, dietetics, chiropractor, and
optometry services were analysed using self-reported data.
“Other services” included remedial massage and naturopathy
services. Cost of allied health services was calculated from the
number of visits and unit cost (Table 2) for each health service
(for self-reported data).
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Table 1: Economic analysis perspectives and data collection sources.
Perspective Date source
Individual Health system Societal Questionnaire at3 and 12 months
Monthly
questionnaire
Medicare
Australia
Hospitalisations
Public hospital — ∗ ∗ — ∗ —
Private hospital — ∗ ∗ — ∗ —
Hospital transport
Ambulance (road and air) — ∗ ∗ — ∗ —
Private car ∗ — ∗ — ∗ —
Taxi ∗ — ∗ — ∗ —
Medical services
General practitioner ∗ ∗ ∗ — ∗ ∗
Medical specialist ∗ ∗ ∗ — ∗ ∗
Imaging ∗ ∗ ∗ — ∗ ∗
Pathology ∗ ∗ ∗ — ∗ ∗
Pharmaceuticals
Medication ∗ ∗ ∗ — ∗ ∗
Allied health services
Physiotherapist ∗ ∗ ∗ — ∗ ∗
Podiatrist ∗ ∗ ∗ — ∗ ∗
Occupational therapy ∗ ∗ ∗ — ∗ —
Speech therapy ∗ ∗ ∗ — ∗ —
Psychology ∗ ∗ ∗ — ∗ —
Dietetic ∗ ∗ ∗ — ∗ —
Chiropractic ∗ ∗ ∗ — ∗ —
Optometry ∗ ∗ ∗ — ∗ —
Other ∗ ∗ ∗ — ∗ —
Other medical services
Dental ∗ ∗ ∗ — ∗ —
Home based care and community
services
Formal care, nurse — ∗ ∗ ∗ — —
Formal care, PCA — ∗ ∗ ∗ — —
Informal care ∗ — ∗ ∗ — —
Meals on wheels — ∗ ∗ ∗ — —
2.5.4. Other Medical Services. Cost of dental visits was
analysed using unit costs from the Australian Government
Department of Veterans Affairs and study data were gathered
from self-reported data taken from resource use question-
naires.
2.5.5. Home Based Care and Community Services. Formal
care included both personal care assistants (PCA) and home
based nursing care. PCA and nurses helped with showering,
dressing, and regular review. The resource use questionnaire
included data on how often home carers visited (twice daily,
daily, every second day, and other). It was assumed the
duration of each visit was 1 hour and the cost for home based
nursing was $27 per hour [22] and for PCA was $25 per
hour [22] (Table 2). “Other community services” included
were the provision of meals by meal on wheels; the daily
cost was assumed to be $16.50 [22]. The number of informal
care hours per week was obtained from the self-reported
questionnaires at 3 and 12 months. The total cost of informal
care was estimated by multiplying total number of informal
care hours over 12 months (multiplying weekly informal care
hours by 52) by an hourly dollar value for informal care of $25
per hour [22] (Table 2).
3. Results
3.1. Participants. 198 people with PD attended the Victorian
Comprehensive Parkinson’s Programme (VCPP) and, of this
population, 150 people who met the inclusion criteria were
invited to participate in the study (Figure 1). From this
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Table 2: Unit costs and assumptions for cost analysis.
Parameter Unit cost ($) Unit Assumption/estimations Data source
Hospitalisations
Public hospital 1627.12 Per day NACWS∗
ALOS ∗ ∗
Australian hospital statistics
2011-12 [20]
Independent Hospital Pricing
Authority [21]
Private hospital 1334.24 Per day
NACWS
ALOS
× 0.82
Private hospital costs are
weighted at 82% of public
hospital costs to account
for doctors charges which
are included in Medicare
data for private patients
Australian hospital statistics
2011-12 [20]
Independent Hospital Pricing
Authority [21]
Hospital transport
Ambulance (road) 688.50 Per transport
Same average cost for both
metropolitan and
rural/remote region
Watts et al. (2013) [22]
Ambulance (air) 2682.30 Per transport — Victoria state government-Health [23]
Private car 0.66 Per kilometre
Average of 30 km for full
journey and same average
cost for all types of motor
vehicles
Australian government
taxation office- car expenses
[24]
Taxi 5.54 Per kilometre Average of 30 km for fulljourney Taxi service commission [25]
Allied health services
Physiotherapy 62.25 Per visit 85% covered by MedicareOut-of-pocket cost is $9.30 MBS item 10960 [26]
Podiatry 62.25 Per visit 85% covered by MedicareOut-of-pocket cost is $9.30 MBS item 10962 [26]
Occupational therapy 62.25 Per visit 85% covered by MedicareOut-of-pocket cost is $9.30 MBS item 10958 [26]
Speech therapy 62.25 Per visit 85% covered by MedicareOut-of-pocket cost is $9.30 MBS item 10970 [26]
Psychology 62.25 Per visit 85% covered by MedicareOut-of-pocket cost is $9.30 MBS item 10968 [26]
Dietetics 62.25 Per visit 85% covered by MedicareOut-of-pocket cost is $9.30 MBS item 10954 [26]
Chiropractic 62.25 Per visit 85% covered by MedicareOut-of-pocket cost is $9.30 MBS item 10964 [26]
Optometry 66.80 Per visit For initial consultation MBS item 10905 [26]
Remedial massage 55.92 Per visit For initial consultationTotal out-of-pocket cost
Worksafe Victoria item M600
[27]
Naturopathy 31.80 Per visit Standard consultationTotal out-of-pocket cost
Worksafe Victoria item N602
[28]
Other medical services
Dental 53.55 Per visit
For a comprehensive oral
examination
Total out-of-pocket cost
Australian Government
Department of Veterans
Affairs-item D011 [29]
Home based care and community services
Formal care, nurse 27.00 Per hour Duration of formal nursingvisit is equal to one hour Watts et al. (2013) [22]
Formal care, PCA 25.00 Per hour Duration of formal nursingvisit is equal to one hour Watts et al. (2013) [22]
Informal care 25.00 Per hour — Watts et al. (2013) [22]
Meals on wheels 16.50 Per day
Cost of meals per day is $16
for 2 meals and $16.50 for 3
meals
Watts et al. (2013) [22]
∗NACWS = national average cost per weighted separation [20]
∗∗ALOS = average length of stay [21].
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Table 3: Population demographics.
Mild Moderate–severe Study population
𝑛 = 35 𝑛 = 52
Mean age (years) 68.1 69.6 69.0
SD 9.4 SD 9.7 SD 9.6
40–65 years (𝑛) 12 (34%) 13 (25%) 25 (29%)
65+ years (𝑛) 23 (66%) 39 (75%) 62 (71%)
Gender
Female (𝑛) 13 (37%) 23 (44%) 36 (42%)
Male (𝑛) 22 (63%) 29 (56%) 51 (58%)
Mini mental state
examination (mean)
28.7 26.7 27.5
SD 1.9 SD 4.0 SD 3.4
Disease duration (years) 2.7 8.2 6.0
SD 3.1 SD 5.4 SD 5.3
Disease severity (HY stage) 35 (40.2%) 52 (59.8%) 87 (100%)
Stage 1 22 (25.3%) 0 22 (25.3%)
Stage 1.5 2 (2.3%) 0 2 (2.3%)
Stage 2 11 (12.6%) 0 11 (12.6%)
Stage 2.5 0 26 (29.9%) 26 (29.9%)
Stage 3 0 16 (18.4%) 16 (18.4%)
Stage 4 0 10 (11.5%) 10 (11.5%)
population 100 people were willing to participate in the study.
From the sample population (𝑛 = 100) 13 participants with-
drewover the 12-month period due to coexisting neurological
conditions (𝑛 = 6) and deceased (𝑛 = 2) and difficulties in
further participation (𝑛 = 5). There were 87 participants who
completed the study at 12 months.
The age of the study population ranged from 43 to 89
years with amean age of 69 years. 71% of the study population
were aged 65 years and older (Table 3).There were 36 females
(42%) and 51 males (58%) who participated in the study.
There were 52 (60%) who had moderate to severe PD (HY
equal or more than 2.5) and 35 (40%) with mild disease (HY
less than 2.5). Most of the participants were in HY stage 2.5
(𝑛 = 26, 30%) while HY stage 1.5 (𝑛 = 2, 2%) had the least
number of participants.
3.2. Resource Utilisation and Cost Analysis
3.2.1. Hospitalisation. The study population had a mean
number of hospital admissions per person of 1.01 (SD 1.31),
with amean total length of stay over 12 months of 7.1 (SD 9.11)
days (Table 4). This differed by severity; for people with mild
disease the mean annual number of days in hospital was 4
days compared to 20 days in the people with more severe PD
(𝑝 < 0.001). Similarly the cost of all hospitalisations (public
and private) over 12 months differed by severity with a mean
annual cost of $6,160 (SD 9,292) in people with mild disease
to $30,061 (SD 40,732) (𝑝 < 0.001) for those withmore severe
PD (Table 5). The mean cost of transport to hospital over
12 months including ambulance, taxi, or private vehicle was
$362 (SD 799), of which themean cost of ambulancewas $338
(SD 791) per person. The single largest reason for hospital
admissions was to optimize/adjust Parkinson medications
(42%), a further 21% of hospitalisations were directly or
indirectly related to PD (falls injuries, pain management,
deep brain stimulation and surgical procedures), and 17%
of hospitalisations were for reasons not related to PD or an
unknown reason. Two participants reported an admission for
deep brain stimulation treatments, each with a LOS of 22
days.
3.2.2. Pharmaceuticals. The mean total cost of all prescribed
medications was $3,644 (SD 2,240) for people with mild
disease and $5,601 (SD 2,573) for more severe cases of PD
over 12 months (𝑝 < 0.001) (Table 5).This comprised a mean
benefit paid per person of $3,144 (SD 2,311) and $5,011 (SD
2,453) for mild and moderate to severe disease, respectively.
Mean out-of-pocket charges were $490 (SD 195) for people
with mild disease and $596 (SD 26) for people with more
severe disease.
3.2.3. Medical Services and Allied Health Services. There was
no difference in the annual number of visits to a general
practitioner for people with mild and moderate to severe
disease; however, people with moderate to severe disease had
more than twice the number of visits to a medical specialist
compared to those with mild disease (28.3 versus 12; 𝑝 <
0.001) (Table 4). The mean annual cost of visits to a medical
specialist was $4,272 (SD 6,251) for people with moderate to
severe disease and $2,706 (SD 2,429) for people with mild
disease (𝑝 = 0.08). The mean annual out-of-pocket cost
for all medical services was $1,179 (SD 1,113) for people with
mild disease and $1,464 (SD 2,309) for people with moderate
disease (𝑝 = 0.25) (Table 5).
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Table 4: Resource utilization related to Parkinson’s disease over 12 months.
Mild
𝑛 = 35
Moderate–severe
𝑛 = 52
𝑝 value
Hospitalisations
Mean number of hospital admissions per person per year 0.60 1.29 <0.001
SD 0.81 SD 1.29
Public hospital 0.11 0.62 0.01
SD 0.32 SD 1.19
Private hospital 0.49 0.67 0.20
SD 0.74 SD 1.12
Mean hospital LOS (days) per person per year 4.43 20.15 <0.001
SD 6.77 SD 26.20
Public hospital LOS 0.86 10.83 <0.001
SD 2.81 SD 24.06
Private hospital LOS 3.57 9.33 0.02
SD 6.56 SD 16.58
Hospital transport (mean number times)
Ambulance (road + air) 0.11 0.58 0.01
SD 0.32 SD 1.18
Private car 0.43 0.98 0.02
SD 0.65 SD 1.39
Taxi 0.09 0.04 0.22
SD 0.37 SD 0.19
Medical services (mean number of visits)
General practice 10.17 10.25 0.47
SD 4.62 SD 4.35
Medical specialist Services 12.00 28.32 <0.001
SD 9.66 SD 18.56
Imaging 4.50 2.98 <0.001
SD 1.90 SD 1.53
Pathology 13.51 18.58 0.05
SD 5.70 SD 16.92
Allied health services (mean number of visits)
Physiotherapy 7.11 10.06 0.15
SD 12.66 SD 12.99
Podiatry 1.06 2.38 0.01
SD 1.86 SD 3.09
Occupational therapy 0.34 0.83 0.06
SD 0.76 SD 1.69
Speech therapy 0.03 0.56 0.04
SD 0.17 SD 1.70
Psychology 0.03 0.30 0.04
SD 0.17 SD 0.82
Dietetics 0.00 0.21 0.12
SD 0.00 SD 1.07
Chiropractic 0.03 0.44 0.09
SD 0.17 SD 1.81
Optometry 0.06 0.04 0.34
SD 0.24 SD 0.20
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Table 4: Continued.
Mild
𝑛 = 35
Moderate–severe
𝑛 = 52
𝑝 value
Other 1 1.02 0.49
SD 1.96 SD 2.57
Other medical services (dental) (mean number of visits) 1.11 0.25 0.08
SD 4.15 SD 1.40
Home based care and community services (mean number of
hours)
Formal care hours, nurse — 7.00 —
SD 30.94
Formal care hours, PCA — 31.00 —
SD 80.60
Informal care hours 96.2 775 0.01
SD 354.53 SD 1492.37
Meals on wheels 11.89 89.00 0.05
SD 50.58 263.41
Inclusion criteria 
Eligible population
Victorian Comprehensive Parkinson 
program in Melbourne, Australia, between 
2007 & 2009 
Enrolments
Allocation
Follow-up population
Recruitment
Study population
Exclusion criteria
Withdrawals :
Non enrolments:
(1) Coexisting neurological 
conditions
(2) Decease category of HY 
stage five
(1) Confirmed diagnosis of idiopathic 
Parkinson
(2) Informed consent to participate in 
the study 
(3) Ability to attend assessment clinics
(4) Ability to complete questionnaires 
over 12 months
Emotional distress n = 5 (3%)
Unwell n = 8 (5%)
Time commitment n = 11 (7%)
Disinterest n = 25 (17%)
Difficulties in further participation n = 5 (5%)
Deceased n = 2 (2%)
Coexiting neurological condition n = 6 (6%)
n = 100
n = 87
n = 198
n = 150
Figure 1: Consort chart; study population.
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Figure 2: Cost of Parkinson’s disease per year per person.
In addition people with PD consulted a range of allied
health practitioners over 12 months. For people with mild
disease the mean total cost of all allied health was $564 of
which $447 (79%) were for physiotherapy. For people with
moderate to severe disease the total cost was $971 with $627
(65%) for physiotherapy and $148 (15%) for podiatry. For both
groups 86% of allied health professional costs were paid out-
of-pocket (Table 5).
3.2.4. Home Based Care, Community Services, and Informal
Care. The study population had an average of 2 hours of
nurse visits per week and 4 hours per week of PCA visits with
amean cost of $121 (SD 698) for nursing care and $463 (1,598)
for PCA care per person per year (Tables 4 and 5). It was
only people with moderate to severe disease who reported
the use of community-based nursing care (Table 4). Informal
care contributed to the largest economic burden in the PD
population. Fifty-two percent of the study population relied
on informal care and for most of them a family member who
lived with them helped with their daily activities. The mean
number of hours was 24 hours per week from the primary
informal caregiver (Table 4). In addition to this, people with
PD reported an average of 3 hours of help from an additional
carer each week. Other community-based services reported
were the provision of meals on a regular basis. Fourteen
percent of the study population reported using this service
at a mean cost of $370 (SD 1,233) per person annually.
3.2.5. Total Cost. Mean total cost per person from a societal
perspective of living with PD over 12 months for the entire
study population was $45,104 (SD 46,446) (Table 5). From
this 66% of costs were attributed to the health system and
34% a burden to households and individuals. Mean total
cost varies according to disease severity (Figure 2); for mild
cases the mean total societal cost was $17,537 (SD 17,397) and
for people with moderate to severe disease was $63,659 (SD
0
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Figure 3: Cost impact of informal care.
50,629). Informal care represented 28% of total costs and dif-
fered according to whether PD was mild (informal care 14%)
or moderate to severe (informal care 30%) (Figures 2 and 3).
4. Discussion
The mean annual cost to the health system for this cohort
of people with PD was $29,916 (SD 36,532) per person in
2012 AUD. In 2016 this is equivalent to $32,300 AUD or
$24,600 USD. In addition annual out-of-pocket expenses
were $15,137 (SD 30,546) per person. This is slightly higher
than a European study that estimated that the total cost
per person with PD was €11,153 per year in 2010 (2012
AUD $14,020). This represented €5,626 direct medical costs,
€4,417 direct nonmedical cost, and €1,109 for indirect costs
(2012 AUD comparison: $7,020; $5,552; and $1,496) [30].
This represents a significant burden to both individuals and
households and to the health care system. In our study two-
thirds of the burden to the health care system was related to
hospitalisation, with medical services and pharmaceuticals
a significant contributor to total costs. As disease severity
increased, the burden to the health system was even greater
at more than three times that for people with mild PD.
The increase in costs as disease progresses is consistent with
findings from other studies with one international study
determining that the direct cost related to PD doubled when
disease progressed from HY stages I to IV [12]. A European
study found that a one-unit increase on the dyskinesia
severity scale (Part IVa of the Unified Parkinson’s Disease
Rating Scale (UPDRS)) resulted in an additional mean total
cost of €737 per patient over a 6-month period [31].
The study participants were admitted to both private
and public hospitals during the study period. There was an
average of one admission per personwith PDover a 12-month
period with an average annual length of stay of 13.5 days.This
compares to the average number of admissions of 0.8 for the
Australian population aged over 55 years in 2009/10 [32, 33].
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The main reason reported for hospitalisation was to adjust
PD medication since frequent changes in symptoms require
alteration of drug dosage and frequency. Other reasons for
admission were for secondary causes including falls (9%).
Other studies have found a higher rate of admissions due to
the complications of PD [8].
Although there was no difference in the number of GP
medical services by disease severity, the number of specialist
medical services for the moderate to severe group was more
than double for people withmild disease. Other than ongoing
management of disease symptoms, a contributing factor
to this difference could be that medical specialist services
provided in private hospitals as part of the inpatient admis-
sion are billed to the national insurer, Medicare Australia.
Although the number of admissions are similar between the
two groups, the moderate to severe groups have five times
the number of days in hospital over 12 months compared to
the participants with mild disease. People with moderate to
severe PD are more likely to receive specialist doctor visits
the more days they are in hospital.
Medication use in the management of PD is ongoing and
costly. The cost of all medications was 11% of the total cost
of PD over the study period. The total annual cost of medi-
cations in this cohort was $418,775, of which the government
paid $370,616 (86% of the total) and the remainder formed
out-of-pocket costs for people with PD.With disease progres-
sion, drug dosage and frequency are likely to increase [34]
and people with PD may need to take other medications to
control the side effects of the drugs (e.g., to relieve nausea and
vomiting and gastric reflux).
Due to disability and progressively increasing mobility
conditions associated with PD, people living with PD often
require allied health services such as physiotherapy, podiatry,
and speech therapy to manage their strength and motor
symptoms and to improve their quality of life [9, 13, 15]. The
mean number of physiotherapy services reported was just
under 9 visits per person per year, which represents less than
one service per month. Factors contributing to this relatively
low number of reported services might be that physiotherapy
services may be provided as part of the hospital episode
and not reported separately. An alternative explanation is
that allied health services are often not claimable through
Medicare Australia; therefore people are likely to face high
out-of-pocket charges over 12 months. In this study allied
health visits represented 27% of the total annual costs of
PD to the household, excluding the burden of informal
care.
From the study population almost 60% had moderate or
severe PD implying that they have disability that affects their
daily living. Participants reported that they were regularly
assisted by a family member, or friends as carers in their day
to day life.The largest burden from the individual/household
perspective was the cost of informal care, estimated at $12,548
per person over 12 months. This was based on the oppor-
tunity cost method for valuing informal care that is on the
assumption that if a family member was not able to provide
this care then it would be the cost of equivalent care provided
by a nursing care attendant. People with moderate to severe
disease reported an average of 775 informal care hours
annually. Only 33% of study participants reported receiving
carer payments from the Australian federal government for
the informal care they provided. In addition to informal care,
participants received home nursing care and other services
such asmeals.Themean total cost of home based community
care services was $950 per person over 12 months. It has been
reported that between 2005 and 2011 the cost of informal care
for peoplewith PDdoubled ($5.4million versus $11.2million)
[8]. This included income in a formal work environment
foregone by carers [35]. The growth reflects the additional
number of people with PD and higher average earnings
in the workforce. A number of studies suggest that the
largest component of household burden was due to providing
informal care and the subsequent loss of earnings [12, 36, 37].
Studies highlight that family relationships can be affected in
the early stage of disease and it is important to be referred
early for home help and counselling and to PD support
groups [38, 39].
The strength of this study is the detail provided in the
resource use questionnaires about the range and costs of
health and community services utilised by people with PD.
Combining these data withMedicare and pharmaceutical use
over 12months and including the frequency of questionnaires
have provided an accurate picture of the resources used by
someone with PD from several perspectives. A limitation was
that participants were referred to a specialist PD clinic and
therefore may not be representative of the PD community.
By separately analysing the cohort by disease severity it is
likely that thosewithmore severe disease are similar to the PD
population withmoderate to severe disease in terms of health
care resource utilisation. We were not able to obtain case
level hospital admission data; therefore, our cost estimates are
based on an average day of stay in anAustralian hospital, with
no reference to reason for admission or comorbidities.
Our population cohort included two people who had
had deep brain stimulation (DBS) so we were not able to
comment on the increased costs likely to be associated with
DBS [40]. As DBS and other device-aided therapies are likely
to become more common therapy for people with PD it
is expected that the direct costs of managing PD will be
higher in the future. In addition an ageing population means
that people with PD are likely to live longer with increased
disease severity.The relationship that we have found between
higher costs and advancing disease and others have found
with increased disability (based on the UPDRS) [31] will be
more apparent in future studies. We recommend that future
studies should determine the relative contribution to costs of
different movement disorders, such as dyskinesia, freezing,
bradykinesia, and postural instability.
5. Conclusion
The annual costs to the health system for people with PD
are high, with more than two-thirds attributed to hospital-
isation. Individuals also face a high out-of-pocket burden
for nonhospital related health services and households face
a burden from providing informal care, which represents
approximately 28% of total costs. The difference in total costs
by disease severity suggests that the burden to society is likely
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to grow in the future with increasing prevalence of chronic
diseases such as PD in an ageing population.
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